Oramed Pharmaceuticals Inc (ORMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Oramed Pharmaceuticals Inc (ORMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH63306D
  • |
  • Pages: 35
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs currently administered only by injection. The company tested its technology through various animal and human studies on its two flagship products, ORMD-0801, an orally ingestible insulin capsule; and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. Oramed is headquartered in Jerusalem, Israel.

Oramed Pharmaceuticals Inc (ORMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Hefei Tianhui Incubator of Technologies Enters into Licensing Agreement with Oramed Pharma 11

Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12

Equity Offering 12

Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 12

Oramed Pharma Raises USD12 Million in Private Placement of Shares 13

Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 14

Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 16

Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 16

Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 18

Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 19

Oramed Pharma Completes Private Placement Of Units US$5 Million 20

Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 20

Oramed Pharma Completes Private Placement For US$3.36 Million 21

Acquisition 22

Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 22

Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 23

D.N.A Biomedical Completes Acquisition Of 47% JV Stake In Entera Bio From Oramed For US$1 Million 24

Oramed Pharmaceuticals Inc-Key Competitors 26

Key Employees 27

Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Recent Developments 29

Corporate Communications 29

Mar 21, 2017: Oramed Appoints Dr. Ronald Law as Chief Strategy Officer 29

Product News 30

06/21/2016: Oramed Announces $6.5 Million Milestone Payment from HTIT 30

Clinical Trials 31

Aug 02, 2016: Oramed Receives Additional $4 Million Milestone Payment From HTIT 31

Jul 28, 2016: Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo 32

May 18, 2016: Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study 33

Apr 05, 2016: Oramed Completes Phase IIb Oral Insulin Study 34

Appendix 35

Methodology 35

About GlobalData 35

Contact Us 35

Disclaimer 35

List of Figures

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

List of Tables

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Oramed Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8

Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Hefei Tianhui Incubator of Technologies Enters into Licensing Agreement with Oramed Pharma 11

Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 12

Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 12

Oramed Pharma Raises USD12 Million in Private Placement of Shares 13

Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 14

Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 16

Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 16

Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 18

Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 19

Oramed Pharma Completes Private Placement Of Units US$5 Million 20

Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 20

Oramed Pharma Completes Private Placement For US$3.36 Million 21

Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 22

Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 23

D.N.A Biomedical Completes Acquisition Of 47% JV Stake In Entera Bio From Oramed For US$1 Million 24

Oramed Pharmaceuticals Inc, Key Competitors 26

Oramed Pharmaceuticals Inc, Key Employees 27

Oramed Pharmaceuticals Inc, Subsidiaries 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Oramed Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16235
Site License
USD 500 INR 32470
Corporate User License
USD 750 INR 48705

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com